Stiff Person Syndrome with Chronic Course: What to Do When First-Line Immunotherapy Fails to Achieve Improvement Goals
This protocol addresses the specific situation in which a patient with Stiff Person Syndrome — presenting with insidious onset and a chronic, stable disease course with mild to moderate functional impairment — has not reached the expected improvement goals after an initial first-line immunotherapy regimen.
Clinical Scenario
The patient presents with an insidious onset of symptoms evolving into a chronic, stable disease course, with mild to moderate functional impairment. Disease onset is typically gradual, progressing over months before stabilising — though exacerbations may occur.
Previous Treatment — Goals Not Reached
The prior treatment line combined symptomatic therapy (including oral agents targeting stiffness and spasms, botulinum toxin injections for focal involvement, and tumour-directed treatment where applicable) with first-line immunotherapy.
That approach did not achieve the required improvement goals:
- Meaningful reduction of stiffness and spasms
- Improved performance on timed functional activities
- Decrease in relevant neuronal antibody titres
This protocol defines the structured next step following that failure.
Next-Step Approach (Partial Overview)
When one first-line immunotherapy agent has not delivered adequate improvement, the evidence-based approach involves switching to a different agent within the first-line immunotherapy group — as these therapies differ in their mechanisms and individual treatment responses are difficult to predict.
The complete protocol — including which agents to consider, sequencing, and response monitoring — is available in the full structured regimen.
References
DOI: 10.1002/mdc3.12629
- Most frequently, there is an insidious onset with a progression over months and a subsequent stable, chronic disease course, but there may be exacerbations.
- Insidious onset, Chronic course, Mild to moderate impairment
- Try other agents of this group
- The various immunotherapies have different modes of action, and it is difficult to predict treatment responses. Therefore, it is common practise to try different immunotherapies, sometimes in combination.
View source ↗